- Home
- MAIA
as of 11-28-2025 12:34pm EST
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 44.9M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 224.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $2.74 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered MAIA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of MAIA Biotechnology Inc. (MAIA)
Director
Avg Cost/Share
$0.98
Shares
10,000
Total Value
$9,785.00
Owned After
399,483
SEC Form 4
Director
Avg Cost/Share
$0.98
Shares
15,000
Total Value
$14,700.00
Owned After
1,349,289
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$0.97
Shares
10,500
Total Value
$10,144.05
Owned After
831,421
SEC Form 4
Director
Avg Cost/Share
$0.99
Shares
10,000
Total Value
$9,900.00
Owned After
1,349,289
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$0.99
Shares
10,000
Total Value
$9,891.00
Owned After
831,421
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$0.92
Shares
1,800
Total Value
$1,656.00
Owned After
831,421
SEC Form 4
Director
Avg Cost/Share
$1.30
Shares
19,230
Total Value
$24,999.00
Owned After
1,349,289
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Luput Cristian | MAIA | Director | Nov 25, 2025 | Buy | $0.98 | 10,000 | $9,785.00 | 399,483 | |
| Smith Stan | MAIA | Director | Nov 25, 2025 | Buy | $0.98 | 15,000 | $14,700.00 | 1,349,289 | |
| Vitoc Vlad | MAIA | Chief Executive Officer | Nov 25, 2025 | Buy | $0.97 | 10,500 | $10,144.05 | 831,421 | |
| Smith Stan | MAIA | Director | Nov 24, 2025 | Buy | $0.99 | 10,000 | $9,900.00 | 1,349,289 | |
| Vitoc Vlad | MAIA | Chief Executive Officer | Nov 24, 2025 | Buy | $0.99 | 10,000 | $9,891.00 | 831,421 | |
| Vitoc Vlad | MAIA | Chief Executive Officer | Nov 21, 2025 | Buy | $0.92 | 1,800 | $1,656.00 | 831,421 | |
| Smith Stan | MAIA | Director | Oct 1, 2025 | Buy | $1.30 | 19,230 | $24,999.00 | 1,349,289 |
Compare MAIA vs Leading Stocks
See how MAIA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MAIA MAIA Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.